GDTC · CytoMed Therapeutics Ltd
Market Cap
$10.17M
Shares
11.93M
Volume · Oct 20
8282
Avg daily vol (3M)
81.1K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.87
Open$0.82
Day$0.81–0.87
52W close$0.72–2.69
Avg vol 30d19K
Short int17K · 0.1% float · 1.1d
Short vol91%
DataApr 2023–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+366.7%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.1%
Year over year · more shares
Price change (1Y)
-62.8%
Trailing year
Short interest
0.1%
Latest settlement · 1.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−13%
below
Price vs 50-day avg
−3%
below
RSI (14)
48
neutral
MACD trend
Negative
52-week position
8%
near low
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−8%
trailing
YTD return
−35%
this year
Relative strength
−16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.14% of float · ▲ +372.4% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
3 holders — mid 3-yr range
Squeeze score
43
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
95%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
12.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−13%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
8%
Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.14% of float · ▲ +372.4% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
3 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 8%
Range high $3
vs 200-day avg -13%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GDTC
this stock
CytoMed Therapeutics Ltd
|
$10.17M | -34.7% | — | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
3
- % held
- 0.1%
- Net QoQ
- -4.5K sh
- Top holder
- Axiom Investment Manageme…
Held
Float
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GDTC | +0.2% | -4.2% | -8.4% | +3.4% | -34.7% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +1.3% | -3.7% | -16.4% | +2.5% | -47.5% |